News Releases

Return to News

Breaking News from OHC

OHC Clinical Trials Breast Cancer Research

Clinical Trial Insight: October 2014 Breast Cancer Trials

Patrick John Ward, MD, PhD, co-director of research at OHC, Blogs, For Physicians, News Releases, 0 comments
October 20, 2014

Ward Patrick J MD PhD

Patrick J. Ward, MD, PhD, OHC Medical Oncologist/Hematologist and Principal Investigator supporting the area of breast cancer clinical research trials.

OHC Research Department’s complex clinical trial menu provides an opportunity for patients in and around the Tri-State to participate in innovative studies which include targeted therapies.

Clinical research of breast cancer has made many recent advances. OHC participated in the CLEOPATRA trial through Roche, which evaluated Pertuzumab and Trastuzumab. The results of this trial were presented at ESMO (European Society for Medical Oncology) in September 2014 which showed that patients on Pertuzumab, Herceptin, and Docetaxel extended the life of previously untreated HER2-positive metastatic breast cancer, by an unprecedented 15.7 months.

Breast cancer is the second most common newly diagnosed cancer and second leading cause of cancer death among women in the US. (American Cancer Society, www.cancer.org). OHC’s Research Department offers a robust Clinical Trial menu for many types of breast cancer, along with Molecular Profiling trials that concentrate on the genetic mutations within the tumor rather than the type of cancer. Research is moving toward a Personalized Precision Medicine approach.

OHC is currently participating in the MONALEESA-2 trial through Sarah Cannon Research Institute. This randomized, double blind, placebo controlled study of LEE011 in combination with Letrozole, both oral agents, is for treatment of post-menopausal women with hormone receptor positive, HER2 negative, advanced breast cancer who have received no prior therapy for advanced disease.

LEE011 is a novel cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. (National Cancer Institute, www.cancer.gov) The CDK4/6 pathway is a mechanism of endocrine resistance in breast cancer.

OHC, in partnership with the Sarah Cannon Research Institute (an internationally recognized leader in development of oncologic targeted therapies), offers multiple programs in clinical trial research, focusing within solid organ oncology diseases, including breast, colorectal/rectal, esophageal/gastric, lung (small cell and non small cell), pancreas, and other varying origins, as well as blood disorders and hematological malignancies.

For More Clinical Research Trial Information, Contact:

S. Maria Izzo, RN
OHC Clinical Research Manager
513-751-2273 x11122

Lynnetta Hart, BS, M.Ed, CCRC
OHC Research Program Director
513-751-2273 x27101


Leave a Reply

Your email address will not be published. Required fields are marked *